Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

    Authors

    R. P. Baughman; K. C. Meyer; I. Nathanson; L. Angel; S. M. Bhorade; K. M. Chan; D. Culver; C. G. Harrod; M. S. Hayney; K. B. Highland; A. H. Limper; H. Patrick; C. Strange;T. Whelan

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abbreviated Journal Title

    Chest

    Keywords

    TUMOR-NECROSIS-FACTOR; PLACEBO-CONTROLLED TRIAL; RABBIT ANTITHYMOCYTE; GLOBULIN; ANTI-TNF THERAPY; PEDIATRIC RENAL-TRANSPLANTATION; RHEUMATOID-ARTHRITIS PATIENTS; CHIMERIC MONOCLONAL-ANTIBODY; ACUTE; CELLULAR REJECTION; PHASE-III TRIAL; CORTICOSTEROID-FREE; IMMUNOSUPPRESSION; Critical Care Medicine; Respiratory System

    Abstract

    Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and inflammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols monitoring to detect manifestations of toxicity and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease

    Journal Title

    Chest

    Volume

    142

    Issue/Number

    5

    Publication Date

    1-1-2012

    Document Type

    Article

    Language

    English

    First Page

    E1

    Last Page

    E111

    WOS Identifier

    WOS:000311010100053

    ISSN

    0012-3692

    Share

    COinS